Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding changes in their shareholdings.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider trading activity and does not contain financial performance data.
Material Changes
The material change reported is the increase in share ownership by specific company officers following the reinvestment of dividends. The transaction occurred on February 4, 2009, at a price of £12.50 per Ordinary share under a Single Company ISA.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a regulatory notification compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: February 4, 2009.
- Share Price: £12.50 per Ordinary share.
- Transaction Type: Purchase of shares via dividend reinvestment (Single Company ISA).
- Directors Involved: Mr. A P Witty (6 shares), Mr. J S Heslop (6 shares), Mr. S M Bicknell (32 shares), Mr. E J Gray (6 shares), and Mr. D S Redfern (6 shares).
- Notification Date: February 5, 2009.